Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple cancer medicines already in clinical testing.

Original title: “Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis”

The acquisition of Tubulis GmbH—Gilead Sciences' latest of the year after buying Arcellx and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.

Original title: “Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis”

Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie's deal with the White House to avoid tariffs. The news comes less than a week after the president announced up to 100% levies on pharma products.

Original title: “AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies”

Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.”

Original title: “Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off”

Evommune went public late last year and is taking on stiff competition in immunology with a recent mid-stage clinical win. Remember biotech IPOs? Back in 2021, more than 100 private companies made the leap to the public markets. In 2025, that number dwindled to only 11 as the industry reeled from a difficult funding environment and investor skittishness. Here, Peña explains the road leading up to Evommune’s IPO, how the company is meeting shareholders’ expectations and what’s on the horizon for the field of immunology. This interview has been edited for brevity and style. LUIS PEÑA: In the broader biotech environment, it’s been a tough haul since the bubble of 2021. Anytime there’s a funding bubble, there comes a post-bubble hangover, and that’s what we had. Or combining with a GLP-1 in metabolic disease can also be incredibly exciting. We love that we’re right there in the middle of it and have the kind of team that can address it. VC sees early signs of a biotech market spring as long winter fades Michael Gibney What’s exciting in biotech is that we continue to forge into new horizons of medicine and healthcare, and it’s still picking up speed as a biotech revolution. But in terms of funding in the post-bubble hangover, a lot of companies were funded that didn’t have the principles to sustain that kind of capital investment.

Original title: “Evommune bucked biotech IPO drought and is focused on the long game | PharmaVoice”

The telehealth provider said hackers gained access to a third-party customer service platform, but medical records remained secure.

Original title: “Hims & Hers says limited data stolen in social engineering attack”

The deal hands Neurocrine a “controversial” medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street analysts.

Original title: “Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout”

While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to Stifel analysts given the potential growth of Vykat XR, approved last year for extreme hunger in patients with Prader-Willi syndrome.

Original title: “Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal”

Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.

Original title: “Pharma Pipeline Stalls for First Time in Decades: Citeline”

Anthropic in October last year iterated its Claude AI model to better cater to biopharma purposes. Sanofi, Novo Nordisk, AbbVie and others already use Claude in their operations.

Original title: “AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch”

Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer’s disease, was previously discontinued after an FDA hold and disappointing early data.

Original title: “Takeda Breaks Up With Denali, Dumps Dementia Drug”

The right incentive program can boost clinical trial enrollment and engagement.

Original title: “Perks persuade participants”

Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early testing, smart IP and regulatory planning, and scalable CMC choices can help founders reach first-in-human faster.

Original title: “Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death””

BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.

Original title: “BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot”

After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M&A action from other big names, including Novartis, Amgen and AbbVie.

Original title: “Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts”

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.

Original title: “Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment”

Drug discovery can be an uphill battle, especially lately given recent upheaval at the FDA and muted investment activity. BioSpace spoke to four industry executives about key issues facing those working in this space, starting with planning around uncertainty.

Original title: “Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges”

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.

Original title: “Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets”

The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved COVID vaccines.

Original title: “Pfizer, BioNTech to pause COVID vaccine study due to low enrollment”